Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

424

HTML

4539

Figures (1-10)

161

Tables (1-2)

173

Sum=5297

Sep 21, 2012 (publication date) through Apr 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 21, 2012; 18(35): 4944-4958
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4944

Full Size Figure Download Figure

Figure 9 Median progression-free survival and overall survival between gem-monotherapy and combination therapy.

Citation: Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4944.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4944